• Lung cancers cause of significant morbidity and mortality worldwide. 1 • Five-year survival of NSCLC is extremely poor for patients diagnosed with metastatic disease. 2
Introduction

Methods
Results
1. GLOBOCAN Lung Cancer Fact Sheet. 2013 . 2. Howlader N, et al. SEER Cancer Statistics Review, 1975 -2012 • Local model adaptation of a validated three health-states partitioned survival analysis model. Structure is described on Figure 1 . • Progression free survival (PFS) was estimated using patient level data from Checkmate 057 trial 3 by measuring PFS events as defined by RECIST 1.1 criteria.
Progressionfree
Progressive
• Proportion of patients occupying the progressive disease (PD) state was calculated as the proportion alive minus the proportion alive and on progression free (PF) health state.
• Selection of parametric model for overall survival (OS) and PFS for nivolumab and docetaxel was based on the best fitting survival models by AIC and BIC statistics and clinical plausibility of the extrapolated survival.
• Inputs for the comparison to pemetrexed, erlotinib, gefitinib, and ramucirumab plus docetaxel were derived from indirect treatment comparisons. 4
• A Saudi Arabian payer perspective was adopted, running the analysis with a 20 years time horizon, discount rate of 5.0% for costs and 3.5% for benefits.
• Mean body weight of 67 kg and a mean height of 165 cm were used.
• Disease management costs, drug administration, drug monitoring and adverse events (AE) management costs were estimated by conducting a Delphi exercise with 8 local medical oncologists to identify and estimate healthcare resource utilization. Local hospital tariffs were then applied to estimate the aggregated costs.
• All costs are expressed in 2016 Saudi Riyals (SAR) • Evaluate the cost-effectiveness of nivolumab for locally advanced or metastatic non-squamous NSCLC after prior chemotherapy from a Saudi Arabia healthcare payer perspective.
Objective
Main assumptions validated with local experts for the base case
• Base case assumes a 2 year cap scenario on nivolumab's duration of treatment based on clinical plausibility. It is assumed that this scenario doesn't affect PFS or OS.
• It is assumed PFS and PD costs are applied as a constant cost • Non-treatment specific utility values for PF and PD were used. Due to lack of local data, US specific utility weights and AEs disutility values from previous NICE submissions were applied.
• It is assumed all AEs are applied as a one-off cost in the first cycle of the model with only grade 3-4 AEs included on the analysis.
Conclusions
• Assuming a Saudi Arabia willingness-to-pay of SAR400,000 / QALY gained, nivolumab would be considered cost-effective against all of the comparators in the analysis
• Given the improvement in clinical efficacy and a favorable ICER, nivolumab is a cost-effective second line treatment option for advance NSCLC from Saudi Arabia healthcare payer perspective.
• These results can assist third-party payers to allocate resources in a more cost-effective manner
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• This study was funded by Bristol-Myers Squibb • Estimated QALYs and survival outcomes are described in Table 1 .
• Estimated costs and cost breakdown are described in Table 2 .
• Treatment acquisition costs for nivolumab, pemetrexed and ramucirumab plus docetaxel represent 58%,44% and 67% of total costs respectively.
• Disease management costs for docetaxel, erlotinib and gefitinib account for 45%, 47% and 58% of total costs; respectively. * Ramucirumab plus docetaxel * Ramucirumab plus docetaxel * Ramucirumab plus docetaxel
• The incremental analysis of nivolumab against the selected comparators is described in Table 3 . Nivolumab increases the QALYs and LYs against all comparators in the range of 0.94 -0.73 and 1.43 -1.03 respectively.
• ICER on the deterministic analysis rages from dominance over ramucirumab plus docetaxel to 344,492 SAR/QALY against gefitinib. ICER against docetaxel is estimated at 331,136 SAR/QALY.
• Deterministic and probabilistic sensitivity analysis for 5,000 iterations were performed. Uncertainty of the ICER appears to be driven by variation in treatment efficacy, resource utilization, body weight and utility weights. Cost-effectiveness acceptability curve is shown on Figure2. 
